1. Home
  2. PSTV vs LPTX Comparison

PSTV vs LPTX Comparison

Compare PSTV & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • LPTX
  • Stock Information
  • Founded
  • PSTV 1996
  • LPTX 2011
  • Country
  • PSTV United States
  • LPTX United States
  • Employees
  • PSTV N/A
  • LPTX N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PSTV Health Care
  • LPTX Health Care
  • Exchange
  • PSTV Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • PSTV 17.0M
  • LPTX 14.7M
  • IPO Year
  • PSTV N/A
  • LPTX N/A
  • Fundamental
  • Price
  • PSTV $0.37
  • LPTX $0.35
  • Analyst Decision
  • PSTV Strong Buy
  • LPTX Hold
  • Analyst Count
  • PSTV 3
  • LPTX 1
  • Target Price
  • PSTV $10.83
  • LPTX N/A
  • AVG Volume (30 Days)
  • PSTV 65.2M
  • LPTX 3.3M
  • Earning Date
  • PSTV 08-13-2025
  • LPTX 08-11-2025
  • Dividend Yield
  • PSTV N/A
  • LPTX N/A
  • EPS Growth
  • PSTV N/A
  • LPTX N/A
  • EPS
  • PSTV N/A
  • LPTX N/A
  • Revenue
  • PSTV $5,206,000.00
  • LPTX N/A
  • Revenue This Year
  • PSTV $14.10
  • LPTX N/A
  • Revenue Next Year
  • PSTV $7.96
  • LPTX N/A
  • P/E Ratio
  • PSTV N/A
  • LPTX N/A
  • Revenue Growth
  • PSTV N/A
  • LPTX N/A
  • 52 Week Low
  • PSTV $0.16
  • LPTX $0.22
  • 52 Week High
  • PSTV $2.31
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 52.77
  • LPTX 52.39
  • Support Level
  • PSTV $0.27
  • LPTX $0.32
  • Resistance Level
  • PSTV $0.38
  • LPTX $0.36
  • Average True Range (ATR)
  • PSTV 0.03
  • LPTX 0.03
  • MACD
  • PSTV 0.01
  • LPTX 0.01
  • Stochastic Oscillator
  • PSTV 81.82
  • LPTX 86.94

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Share on Social Networks: